Feb. 17 at 2:52 AM
$AMRN SLIDE #3, Key Takeaways (VAZKEPA – Icosapent | Growth by Region)
1️⃣ Explosive National Growth (2022 → 2025)
You’ve got a textbook launch curve here:
• 2022: Minimal baseline (pilot / early access phase)
• 2023: Strong market entry
• 2024: Breakout year
• 2025: Massive scale-up across all regions
This looks like successful market adoption + prescriber confidence compounding over time.
________________________________________
2️⃣ Top Growth Engines (2025 Volume Leaders)
Biggest contributors in 2025:
• 🥇 Midlands – 1,642,551
• 🥈 North West – 1,062,460
• 🥉 North East & Yorkshire – 925,610
• 🔹 South East – 514,258
• 🔹 South West – 352,834
• 🔹 East of England – 198,736
• 🔹 London – 110,224
👉 The Midlands alone is carrying ~30%+ of total UK
Strategic Implications (What This Slide Is Really Saying)
✅ Your launch strategy worked nationally
⚠️ London is a growth bottleneck
🎯 Midlands + North West are scale engines
📈 North East & Yorkshire is a momentum market.
